Fig. 11: Heatmap of the drug response prediction and treatment received and percent of tumor burden change following therapy from subjects in the physician-choice arm. | npj Precision Oncology

Fig. 11: Heatmap of the drug response prediction and treatment received and percent of tumor burden change following therapy from subjects in the physician-choice arm.

From: ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial

Fig. 11

A Heat map of the Drug Response Prediction and Treatment Received. Each row represents a different participant in the Physician-Choice group. Each participant is labeled with a unique progressive number. Subjects labeled “NR” are non-responders (SD and PD), while those labeled “R” are responders (CR and PR) evaluated as per RECIST 1.1. The various drug/drug combinations used in the study are represented in the columns. The treating physicians were blinded to test results. The “X” represents the drug regimen administered to each subject. The color of the cells corresponds to the predicted cell kill % of the drug(s). The colored cells without the “X” show other potential drug regimens that were predicted, but not administered. B Percentage of tumor burden change as per RECIST 1.1 measurements following treatment received from subjects in the physician-choice group. Each column represents a different participant. Each participant is labeled with a unique progressive number. Referent lines are drawn to indicate complete response (CR, purple columns, 100% tumor decrease), partial response (PR, orange columns, ≥ 30% tumor decrease), stable disease (SD, blue columns, 30% tumor decrease to 20% tumor increase), and progressive disease (PD, purple columns, ≥ 20% tumor increase).

Back to article page